Scholarlink

<p>Murine Double Minute 2 (MDM2) inhibition is recognized as a potential preventive and therapeutic approach for several malignant neoplasms in humans. Targeting MDM2 is a viable strategy for cancer treatment, as it can be regulated by both p53-mediated and p53-independent pathways. Despite MDM2’s crucial role in carcinogenesis, research into pharmacological MDM2 inhibitors has been challenging. Since there are currently no FDA-approved MDM2 inhibitors available on the market, more research in this field is necessary. In several human cancer models, various natural substances have demonstrated the ability to inhibit MDM2. They include Glycyrrhizic Acid (GA), Parthenolide (PTL), chalcones, hoiamides, Isokotomolide A (IKA), Genistein (GT), Flavopiridol, Theaflavin (TF), Curcumin, <i>Camellia sinensis (C.sinensis)</i>, and Sesquiterpene Lactones (STLs). Natural extracts have also been investigated as possible lead sources for pharmacological MDM2 inhibitors, in addition to particular molecules. The goal of this review is to provide a comprehensive analysis of natural MDM2 inhibitors, including their pharmacokinetic properties, binding mechanisms, and challenges in their development. Possible methods to enhance their effectiveness and therapeutic applications are also explored.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Murine double minute 2 (MDM2) as an appealing target for natural products in cancer treatment

  • 期刊论文

  • 发表日期：

    2026年3月7日

查看全文
  • Tejveer Singh,
  • Areena Turk,
  • Deepika Sharma,
  • Deeksha Pal,
  • Isha Rani,
  • Katrin Sak,
  • Bunty Sharma,
  • Damandeep Kaur,
  • Shafiul Haque,
  • Hardeep Singh Tuli,
  • Ujjawal Sharma

摘要

Murine Double Minute 2 (MDM2) inhibition is recognized as a potential preventive and therapeutic approach for several malignant neoplasms in humans. Targeting MDM2 is a viable strategy for cancer treatment, as it can be regulated by both p53-mediated and p53-independent pathways. Despite MDM2’s crucial role in carcinogenesis, research into pharmacological MDM2 inhibitors has been challenging. Since there are currently no FDA-approved MDM2 inhibitors available on the market, more research in this field is necessary. In several human cancer models, various natural substances have demonstrated the ability to inhibit MDM2. They include Glycyrrhizic Acid (GA), Parthenolide (PTL), chalcones, hoiamides, Isokotomolide A (IKA), Genistein (GT), Flavopiridol, Theaflavin (TF), Curcumin, Camellia sinensis (C.sinensis), and Sesquiterpene Lactones (STLs). Natural extracts have also been investigated as possible lead sources for pharmacological MDM2 inhibitors, in addition to particular molecules. The goal of this review is to provide a comprehensive analysis of natural MDM2 inhibitors, including their pharmacokinetic properties, binding mechanisms, and challenges in their development. Possible methods to enhance their effectiveness and therapeutic applications are also explored.